Theravance Biopharma (NASDAQ:TBPH) Receives “Buy” Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research report released on Tuesday,Benzinga reports. BTIG Research currently has a $40.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on TBPH. Oppenheimer initiated coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target for the company. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $19.99 on Tuesday. The business’s 50-day simple moving average is $19.07 and its 200 day simple moving average is $15.81. The company has a market cap of $1.01 billion, a P/E ratio of 35.07 and a beta of 0.15. Theravance Biopharma has a one year low of $7.90 and a one year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The firm had revenue of $19.99 million during the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. Analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the transaction, the senior vice president owned 277,695 shares in the company, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently added to or reduced their stakes in TBPH. Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after purchasing an additional 54,152 shares during the period. Geode Capital Management LLC raised its stake in Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after acquiring an additional 3,416 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 6.2% in the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock worth $11,193,000 after acquiring an additional 44,634 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Theravance Biopharma in the third quarter worth about $10,611,000. Finally, UBS Group AG boosted its stake in Theravance Biopharma by 10.9% in the fourth quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock valued at $10,673,000 after acquiring an additional 56,255 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.